In the realm of pharmaceutical development, the identification and synthesis of specific molecular agents are paramount for creating effective treatments. YHO-13177 (CAS: 912287-56-0), known for its potent and specific inhibition of Breast Cancer Resistance Protein (BCRP/ABCG2), plays a crucial role not just as a research tool, but also as a significant pharmaceutical intermediate in the pursuit of novel anticancer therapies. Its chemical structure and biological activity make it a valuable building block for designing next-generation drugs aimed at combating multidrug resistance (MDR).

The significance of YHO-13177 as a pharmaceutical intermediate for oncology drugs lies in its targeted mechanism. BCRP is implicated in the resistance of various cancer types to a broad spectrum of chemotherapeutic agents. By inhibiting BCRP's efflux activity, YHO-13177 can enhance the intracellular concentration and efficacy of these drugs. This fundamental action forms the basis for developing combination therapies or designing modified drug molecules that bypass or overcome BCRP-mediated resistance. Pharmaceutical chemists often utilize such intermediates to synthesize prodrugs or analogues with improved pharmacokinetic properties or enhanced target specificity.

The research surrounding YHO-13177 CAS 912287-56-0 highlights its potential beyond direct therapeutic use. Its role as an intermediate allows for the exploration of structure-activity relationships, where modifications to the YHO-13177 scaffold could lead to compounds with even greater potency, selectivity, or a broader spectrum of activity against different efflux pumps. This approach is central to modern drug discovery, where intermediates serve as starting points for creating libraries of compounds that can be screened for optimal therapeutic profiles. The ability to buy YHO-13177 online from specialized chemical manufacturers facilitates this process, providing researchers and developers with access to this critical component.

Furthermore, the investigation into drug resistance mechanisms in oncology continually reveals new targets and pathways. As our understanding of cancer cell biology deepens, the demand for specific molecular tools and intermediates like YHO-13177 grows. These compounds are essential for validating drug targets, testing hypotheses related to drug efflux, and ultimately, for synthesizing new chemical entities with improved therapeutic outcomes. The precise action of YHO-13177 against BCRP makes it an indispensable component in the pipeline for developing drugs that can overcome resistance, offering hope for patients with otherwise untreatable cancers.

In summary, YHO-13177's dual role as a research chemical and a pharmaceutical intermediate underscores its importance in the ongoing battle against cancer. Its specific inhibition of BCRP provides a critical advantage in understanding and tackling drug resistance, paving the way for innovative therapeutic solutions.